Page 2850

Are Offspring of Obese Moms Pre-Programmed for Obesity and Metabolic Disease?

0





Are Offspring of Obese Moms Pre-Programmed for Obesity and Metabolic Disease?

Umbilical Cord Stem Cells Offer Clues to Mechanism by Which Obesity and Diabetes are Passed to Next Generation


BOSTON, June 9, 2015 /PRNewswire-HISPANIC PR WIRE/ — The evidence is clear that the children of obese parents are prone to obesity themselves, placing them at higher risk for type 2 diabetes, but how and why this occurs remains under investigation. A study being presented at the American Diabetes Association’s 75th Scientific Sessions found evidence suggesting that the in utero environment in obese mothers may program a child’s cells to accumulate extra fat or develop differences in metabolism that could lead to insulin resistance.

Logo – http://photos.prnewswire.com/prnh/20141105/156803LOGO

“One of the questions that needs to be explored is how children of obese mothers may be at risk for becoming obese as a result of factors that occur even before they are born,” said Kristen E. Boyle, PhD, assistant professor at the University of Colorado School of Medicine. “Our study looked at the mechanism by which children may be preprogrammed for increased obesity risk, because of changes occurring in utero.”

Boyle and her team took stem cells from donated umbilical cords of the babies of normal-weight and obese mothers and grew them into fat and muscle cells in the lab. They found 30 percent higher fat content in both types of cells in the offspring of mothers who were obese at their first prenatal visit, compared to the cells of offspring of normal-weight moms. They are continuing to evaluate the data to determine if these cells likewise show evidence of altered metabolism.

“At this point, because this is fairly preliminary, we don’t know how these differences in cells grown in the lab correspond to the physiology of these children after birth,” Boyle said. “But it’s clear that there is an inherent propensity toward more fat content in the cells from offspring of obese moms, in culture. We also know that the fat accumulation in these cells corresponded to the baby’s fat mass at birth. The next step is to follow these offspring to see if there is a lasting change into adulthood.”

Boyle and her team expect to soon have additional information on how the cells use fat for energy production and whether this contributes to the greater fat accumulation in the cells from the offspring of obese mothers. They are continuing to conduct a full, metabolic assessment of the cells to determine whether the cells in the offspring of obese moms display inflammation, insulin resistance or other metabolic differences.

The American Diabetes Association is leading the fight to Stop Diabetes® and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. For the past 75 years, our mission has been to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (800-342-2383) or visit diabetes.org. Information from both these sources is available in English and Spanish.


Denny’s “Kids Eat Free” Tuesdays Just Got A Whole Lot More Fun

0
Denny's Kids Eat Free





Denny’s “Kids Eat Free” Tuesdays Just Got A Whole Lot More Fun

America’s Diner partners with DreamWorks Animation to offer Spanish-language interactive kids menu and activity book featuring the adored
Penguins of Madagascar characters


SPARTANBURG, S.C., June 9, 2015 /PRNewswire-HISPANIC PR WIRE/ — Denny’s, America’s family diner, has teamed up with DreamWorks Animation to promote their “Kids Eat Free” program. “Kid’s Eat Free,” available nationwide on Tuesdays from 4pm-10pm, allow for parents and kids to enjoy an affordable dining-out experience on Tuesday nights, and select from Denny’s many kid-friendly options.

Eating together as a family is central to Latinos and serving their children tasty and healthy food straight from the kitchen is paramount to Latina moms. Denny’s “Kids Eat Free” DreamWorks menu includes breakfast, lunch and dinner plates and nourishing side options to balance the meal – fresh fruits, vegetables, juices, salad, yogurt and milk.

To enhance the dining experience, the kid’s activity book is chockfull of themed puzzles and interactive games featuring DreamWorks character favorites. And, parents can download the free DreamWorks COLOR App to watch their children’s color drawings come to 3D life, enjoy family-friendly activities, and view original movie content and more.

In addition, families have the chance to win great DreamWorks prizes by visiting the Spanish-language Denny’s Latino Facebook Page for a limited time only: June 10 – June 16 and sharing their personal stories/memories of dining as a family at Denny’s.

“Denny’s is a family-focused diner because, like our Latino clientele, we know the importance of sharing a meal together as a family. Our Spanish-language kids menu offers made-to-order meals straight from the kitchen, and the widely popular DreamWorks characters,” said John Dillon, @DillonJohnW, senior vice president and chief marketing officer of Denny’s Corporation. “We invite families to take the evening off from cooking, and join us at our table during ‘Kids Eat Free’ on Tuesdays. The little ones will enjoy their yummy meal while interacting with their favorite Penguins of Madagascar characters found throughout the new menu and activity book.”

For more information about Denny’s new DreamWorks kids menu or to find a restaurant near you, please visit www.dennys.com. To download the DreamWorks COLOR App, please visit www.dreamworkscolor.com.

About Denny’s Corp.
Denny’s is one of America’s largest full-service family restaurant chains, currently operating 1,700 franchised, licensed and company-owned restaurants across the United States, Canada, Chile, Costa Rica, Curacao, Dominican Republic, El Salvador, Guam, Honduras, Mexico, Puerto Rico and New Zealand. For further information on Denny’s, including news releases, please visit the Denny’s website at www.dennys.com or the brand’s social channels via Facebook, Twitter, Tumblr, Pinterest, Instagram or YouTube.

NOTE TO EDITORS: Multimedia assets are available at:: http://hispanicprwire.com/en/multimedia/


Vaccines Needed To Keep Serious Diseases From Returning

0






NEW YORK, June 9, 2015 /PRNewswire-HISPANIC PR WIRE/ — The outbreak of measles that began in California and spread to several other states earlier this year demonstrated that vaccine-preventable diseases are not a thing of the past, as many Americans seem to believe.  Some potentially disabling and fatal infectious diseases are making a comeback, and vaccines are critically important to preventing these once-common childhood diseases from threatening the public’s health again. 

Logo – http://photos.prnewswire.com/prnh/20150409/197662LOGO

“These recent outbreaks teach us that these diseases are still around and can show up anywhere,” said Mark H. Sawyer, MD, professor, Clinical Pediatrics, Division of Infectious Diseases, University of California, San Diego School of Medicine-Rady Children’s Hospital. “Making sure everyone is immunized can prevent future widespread outbreaks and create herd immunity that will protect vulnerable people who can’t get the vaccine because their immune systems are suppressed or because they are too young to be immunized.”

Even pregnant women should be immunized, according to Sonja Rasmussen, MD, MS, Editor-in-Chief, Morbidity and Mortality Weekly Report (MMWR), U.S. Centers for Disease Control and Prevention. “A pregnant woman should get all the recommended vaccinations, including a pertussis booster and an annual flu shot.  Being immunized not only protects her health, it protects her baby from the day it’s born,” Dr. Rasmussen said.

The two leading experts on vaccines made their comments and presented their latest research at a luncheon sponsored by the March of Dimes.  The March of Dimes funded the development of the polio vaccine and encourages parents to keep their children and the community of children safe by following the schedule of vaccination recommended by the American Academy of Pediatrics.

The U.S. Centers for Disease Control and Prevention (CDC) calls vaccines one of the 10 greatest health achievements of the 20th century. Yet cases of measles and whooping cough are increasing because of declining immunization rates.

“Vaccines defeated diseases like polio, measles, pertussis and just recently rubella, (German measles),” says Edward R. B. McCabe, MD, PhD, March of Dimes Chief Medical Officer. “Those vaccines were successful because of consistent, long-term efforts. This recent lapse in our vigilance and commitment allowed these deadly diseases to return and spread. The March of Dimes remains a staunch advocate for vaccination of all children and pregnant women in accordance with the CDC’s recommendations.”

With chapters nationwide and its premier event, March for Babies, the March of Dimes works to improve the health of babies by preventing birth defects, premature birth and infant mortality. For the latest resources and information, visit marchofdimes.com or nacersano.org. Find us on Facebook and follow us on Twitter.


Primary Endpoint met for Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

0





Primary Endpoint met for Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

TECOS Results presented at the 75th Scientific Sessions of the American Diabetes Association convention, Boston, USA

Oxford University and Duke Clinical Research Institute News Release


ALEXANDRIA, Va., June 8, 2015 /PRNewswire-HISPANIC PR WIRE/ — Treatment with sitagliptin, a DPP-4 inhibitor, versus placebo for median 3 years in 14,671 patients with type 2 diabetes (T2DM) and established cardiovascular (CV) disease showed non-inferiority for the primary composite cardiovascular endpoint of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), and no increase in hospitalization for heart failure in the sitagliptin group.

Logo – http://photos.prnewswire.com/prnh/20141105/156803LOGO

Researchers at the University of Oxford Diabetes Trials Unit (DTU) and the Duke Clinical Research Institute (DCRI) have found that among patients with T2DM and established CV disease, addition of sitagliptin to usual care did not impact on the risk for major adverse CV events, hospitalization for heart failure or adverse events. Concerns about possible links between incretin-based therapies and effects on the pancreas have been raised. In TECOS, acute pancreatitis and pancreatic cancer were uncommon and not statistically significant different between groups. Numerically, in the sitagliptin group there were more patients with acute pancreatitis and fewer patients with pancreatic cancer than in the placebo group.

Professor Rury Holman of Oxford University, Joint Chair of the study, commented ‘TECOS provides reassurance that sitagliptin may be used safely to improve blood glucose levels in a diverse group of T2DM patients at high cardiovascular risk without impacting on rates of cardiovascular complications or heart failure.’

Professor Eric Peterson, DCRI Executive Director at Duke University and Joint Chair of the study, stated: ‘TECOS is an excellent example of academic and industry collaborative research.’

TECOS was designed, run, and analyzed independently by DTU and DCRI, in an academic collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, (known as MSD outside the United States and Canada), who sponsored and funded the study.

The TECOS results will be published online in the New England Journal of Medicine on Monday 8th June 2015. A slide set reflecting the data presented at the American Diabetes Association will be available to download from http://www.dtu.ox.ac.uk/TECOS/ after 6.30pm EDT (11.30pm BST) the same day.

Notes for Editors

For more information please contact:

The News and Information Office, University of Oxford, (+44) 1865 270046. [email protected].  

Susan Landis, Strategic Communications. [email protected]. (+1) 919-668-5759.

*The American Diabetes Association is holding its 75th Annual Scientific Sessions in Boston, USA, on June 5 – 9 2015. See http://scientificsessions.diabetes.org for more information. 

*The American Diabetes Association is leading the fight to Stop Diabetes® and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. For the past 75 years, our mission has been to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (800-342-2383) or visit diabetes.org. Information from both these sources is available in English and Spanish.

*Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) was an event-driven trial conducted in adults with type 2 diabetes and a history of cardiovascular (CV) disease in a usual care setting. The trial was designed to assess the CV safety of long-term treatment with sitagliptin (JANUVIA®) when added to existing therapy compared with placebo. The primary composite CV outcome was the time to the first confirmed event of CV-related death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. TECOS enrolled 14,724 participants from 38 countries between December 2008 and July 2012 with a median follow-up of three years. See TECOS-study.org

*Funding was provided by Merck & Co., Inc., Kenilworth, NJ, USA, (known as MSD outside the United States and Canada) who market sitagliptin (JANUVIA®). See www.merck.com

*The Duke Clinical Research Institute (DCRI) is the world’s largest academic clinical research organization. DCRI research spans multiple disciplines, from pediatrics to geriatrics, primary care to subspecialty medicine, and genomics to proteomics. The DCRI is also home to the Duke Databank for Cardiovascular Diseases, the largest and oldest institutional cardiovascular database in the world, which continues to inform clinical decision-making 40 years after its founding. The DCRI has conducted studies at more than 37,000 sites in 65 countries; completed more than 970 phase I-IV clinical trials, studies of patient outcomes and analyses of comparative effectiveness; managed national patient registries; enrolled more than 1.2 million patients in DCRI studies; and published more than 9,000 papers in peer-reviewed journals.

*The Diabetes Trials Unit (DTU) is a fully registered UKCRC Clinical Trials Unit and a founder member of Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM). It is one of only a handful of Academic Research Organisations (AROs) worldwide that specialise in performing diabetes-related mega trials. The DTU designs, runs and analyses large-scale Phase III/IV interventional clinical outcome trials nationally and internationally, often in collaboration with other AROs and pharmaceutical companies. Currently the DTU is undertaking 4 large-scale cardiovascular outcome trials in 40 countries recruiting more than 48,000 patients. See www.dtu.ox.ac.uk.

*OCDEM (Oxford Centre for Diabetes, Endocrinology and Metabolism) is a pioneering centre at Oxford University which combines clinical care, research and education in diabetes, endocrine and metabolic diseases. By promoting world-class research, it aims to enhance understanding of these diseases and to accelerate the search for new treatments and cures. See www.ocdem.ox.ac.uk

 


First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

0






First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Popular Glucose-Lowering Drugs Also Show No Risk of Hypoglycemia or Pancreatic Injury, and Modest Benefit for Weight Compared to Placebo


BOSTON, June 8, 2015 /PRNewswire-HISPANIC PR WIRE/ — One member of a widely prescribed class of drugs used to lower blood glucose levels in people with diabetes has a neutral effect on heart failure and other cardiovascular problems, according to the first clinical trial to examine cardiovascular safety in a GLP-1 receptor agonist, presented at the American Diabetes Association’s 75th Scientific Sessions.

Logo – http://photos.prnewswire.com/prnh/20141105/156803LOGO

The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) study also found a modest benefit for weight control, and no increase of risk for hypoglycemia or pancreatic injury in those who took lixisenatide, one of several GLP-1 receptor agonists being prescribed around the world to treat people with type 2 diabetes. GLP-1 receptor agonists are derived from gut hormones and may be used as a secondary therapy when other medications fail to sufficiently lower blood glucose levels.

“There has been a cloud of suspicion over all new diabetes drugs, including GLP-1 agonists, over whether they may increase the risk for cardiovascular problems,” said Marc Pfeffer, MD, PhD,  Dzau Professor of Medicine at Harvard Medical, senior physician in cardiology at Brigham and Women’s Hospital and principal investigator for the ELIXA trial. “There has also been some hope that some of these drugs may improve cardiovascular health. GLP-1 receptor agonists were being used around the world while CVD safety had yet to be established. This is the first report of a clinical trial designed to assess cardiovascular outcomes in this class of drugs and we have shown that patients and their healthcare providers should have no cause for concern, even if they are at high risk for heart-related problems.”

Specifically, the ELIXA study found no increased risk for cardiovascular death, heart attack, stroke, unstable angina (chest pain) or heart failure in people with type 2 diabetes who had recently experienced acute coronary syndrome events (an umbrella term referring to when blood supplied to the heart muscle is suddenly blocked) and were therefore at high risk for additional heart problems. The study examined 6,068 people from 49 countries, randomly assigning them to lixisenatide or placebo, with a follow-up period of more than two years.

Heart disease and stroke are the number one causes of death and disability among people with type 2 diabetes, who are two to four times more likely than those who do not have diabetes to suffer from these conditions. Because of this, the U.S. Food and Drug Administration has recently augmented cardiovascular surveillance for new drugs prescribed to treat elevated blood glucose in patients with type 2 diabetes, including GLP-1 receptor agonists.

The ELIXA trial also showed that those who took lixisenatide were not more likely to have problems with hypoglycemia (low blood glucose) than those who took placebo, despite better blood glucose control.

“Knowing these drugs can be prescribed safely gives physicians another tool to further lower glucose without producing more hypoglycemia, a potential complication of improved glycemic control,” said Eldrin Lewis, MD MPH, Associate Professor of Medicine, Harvard Medical School, Advanced Heart Disease section of Cardiovascular Division at Brigham and Women’s Hospital. “These drugs can provide a very important adjunct to therapy. We want to get people to target to minimize the future consequences of diabetes, but we don’t want to add any additional risks in doing so.”

The ELIXA trial also found no increase in pancreatitis or cancers and a modest benefit in terms of weight gain, said Matthew Riddle, MD, Professor of Medicine, in the Division of Endocrinology, Diabetes, & Clinical Nutrition, at Oregon Health & Science University. Those taking lixisenatide did not gain weight, while those taking placebo did.

Those taking lixisenatide did, however, report a higher number of episodes of nausea and vomiting, common side effects for GLP-1 receptor agonists. “Nausea and vomiting sometimes caused patients to discontinue the medication,” said Riddle, “but in terms of serious reactions or pancreatic problems, there was no difference between the two groups and no increased risk.”

Dr. Pfeffer will lead a symposium on The Evaluation of Lixisenatide in Acute Coronary Syndrome – The Results of ELIXA on Monday, June 8 from 2:15 – 4:15 p.m. The ELIXA results will be followed by results from another cardiovascular safety trial, Results from the Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin (TECOS) from 4:30 – 6:30 p.m.

The American Diabetes Association is leading the fight to Stop Diabetes® and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. For the past 75 years, our mission has been to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (800-342-2383) or visit diabetes.org. Information from both these sources is available in English and Spanish.


Club de Cuervos, a Netflix Original Series From Mexican Filmmaker Gaz Alazraki, to Debut in All Netflix Territories on August 7

0





Club de Cuervos, a Netflix Original Series From Mexican Filmmaker Gaz Alazraki, to Debut in All Netflix Territories on August 7


U.S. Members Will Also Be Able to Enjoy an Expanded Selection of Spanish-Language Titles Beginning in June


BEVERLY HILLS, Calif., June 8, 2015 /PRNewswire-HISPANIC PR WIRE/ — Netflix, Inc. (Nasdaq: NFLX), the world’s leading Internet television network, will premiere the outrageous original Spanish-language series, Club de Cuervos, from Mexican filmmaker Gaz Alazraki (“Nosotros los Nobles”), in all Netflix territories on August 7, 2015.

Logo – http://photos.prnewswire.com/prnh/20101014/SF81638LOGO

Balanced equally among comedy and drama, Club de Cuervos brings viewers into the middle of a no-holds-careed battle among members of a wealthy family, triggered by the death of the patriarch, to determine who will gain control of the beloved professional soccer team, The Cuervos of Nuevo Toledo. The series stars Luis Gerardo Mendez and Mariana Trevino, and features Stephanie Cayo, Daniel Gimenez Cacho, Ianis Guerrero and Antonio de la Vega.

In addition, Netflix is now starting to offer a more robust selection of Hispanic titles to its U.S. members, ranging from tele-series and novelas, to kids shows, comedies, documentaries and movies as a result of expanded partnerships with leading broadcasters Univision, UniMas, Telemundo and others.

Among the fantastic programming Netflix U.S. members can now enjoy are iconic titles that have touched generations of Hispanics such as El Chapulin Colorado, Teresa, Rebelde, Maria La Del Barrio, La Usurpadora, Rubi; more recent favorites, including El Senor de los Cielos, La Reina del Sur, La Viuda Negra, Duenos del Paraiso, Senora Acero, Los Heroes Del Norte, El Cartel, El Cartel 2, Pablo Escobar, El Patron del Mal, Operacion Jaque, La Prepago, Los Caballeros Las Prefieren Brutas; and the US Hispanic version of the Brazilian classics like El Clon, among many others.

“Generations have loved shows like El Chavo and we are confident that they will enjoy recent titles like La Dictadura Perfecta as well as the latest addition to our originals slate, Club de Cuervos,” said Ted Sarandos, Chief Content Officer at Netflix. “We’re thrilled to be working with Univision and Telemundo as well as a range of amazing Latin American content creators to enrich our Hispanic content mix in the U.S., allowing families to watch some of their favorite shows together when and how they want.”

In addition to the broadened slate of Hispanic series and films, acclaimed Netflix Original Series, including Orange is the New Black, Marvel’s Daredevil, House of Cards, Bloodline, Grace and Frankie, and Sense8, are also available to U.S. members with Spanish-language dubbing and subtitles.

All thirteen episodes of season one of Club De Cuervos will be available exclusively on Netflix. The Alazraki Productions series was created by Gaz Alazraki and Mike Lam and executive produced by Gaz Alazraki, Leonardo Zimbron, Mike Lam, Jay Dyer, with producers Moises Chiver and Monica Vargas.

About Netflix
Netflix is the world’s leading Internet television network with over 62 million members in over 50 countries enjoying more than 100 million hours of TV shows and movies per day, including original series, documentaries and feature films. Members can watch as much as they want, anytime, anywhere, on nearly any Internet-connected screen. Members can play, pause and resume watching, all without commercials or commitments.


If you purchased Flexible Polyurethane Foam directly from any Flexible Polyurethane Foam manufacturer from January 1, 1999 through July 31, 2010, you could be a Class Member in six proposed class action settlements

0





If you purchased Flexible Polyurethane Foam directly from any Flexible Polyurethane Foam manufacturer from January 1, 1999 through July 31, 2010, you could be a Class Member in six proposed class action settlements


WASHINGTON, June 8, 2015 /PRNewswire-HISPANIC PR WIRE/ — The following statement is being issued by BOIES, SCHILLER & FLEXNER LLP and QUINN EMANUEL URQUHART & SULLIVAN, LLP regarding the In re Polyurethane Foam Antitrust Litigation.

YOUR LEGAL RIGHTS ARE AFFECTED. PLEASE READ THIS NOTICE CAREFULLY.

Plaintiffs in this class action have reached six proposed settlements in a class action lawsuit concerning certain producers of Flexible Polyurethane Foam and Flexible Polyurethane Foam products. Plaintiffs have reached settlements with FFP Holdings, LLC (“FFP”), Foamex Innovations, Inc. (“FXI”), Future Foam, Inc. (“Future Foam”), Hickory Springs Manufacturing Company (“Hickory Springs”), Mohawk Industries, Inc. (“Mohawk”), and Woodbridge Foam Corporation, Woodbridge Sales & Engineering, Inc., and Woodbridge Foam Fabricating, Inc. (collectively “Woodbridge”).

What are the Benefits of the Settlements?

Settlement 1: FFP – The “FFP Settlement” is among Plaintiffs, the Certification Class1, the FFP Settlement Class, and FFP only. Plaintiffs, Certification Class Members, and FFP Settlement Class Members will release FFP from all pending claims, and in exchange FFP has agreed to: (i) pay $16,000,000 to a fund to compensate FFP Settlement Class Members; and (ii) provide limited cooperation at or before trial.

Settlement 2: FXI – The “FXI Settlement” is among Plaintiffs, the Certification Class, the FXI Settlement Class, and FXI only. Plaintiffs, the Certification Class, and FXI Settlement Class Members will release FXI from all pending claims, and in exchange FXI has agreed to: (i) pay $60,000,000 to a fund to compensate FXI Settlement Class Members; and (ii) provide limited cooperation at or before trial.

Settlement 3: Future Foam – The “Future Foam Settlement” is among Plaintiffs, the Certification Class, the Future Foam Settlement Class, and Future Foam only. Plaintiffs, Certification Class Members, and Future Foam Settlement Class Members will release Future Foam from all pending claims, and in exchange Future Foam has agreed to: (i) pay $32,000,000 to a fund to compensate Future Foam Settlement Class Members; and (ii) provide limited cooperation at or before trial.

Settlement 4: Hickory Springs – The “Hickory Springs Settlement” is among Plaintiffs, the Certification Class, the Hickory Springs Settlement Class, and Hickory Springs only. Plaintiffs, the Certification Class, and Hickory Springs Settlement Class Members will release Hickory Springs from all pending claims, and in exchange Hickory Springs has agreed to: (i) pay $19,500,000 to a fund to compensate Hickory Springs Settlement Class Members; and (ii) provide limited cooperation at or before trial.

Settlement 5: Mohawk – The “Mohawk Settlement” is among Plaintiffs, the Certification Class, the Mohawk Settlement Class, and Mohawk only. Plaintiffs, Certification Class members, and Mohawk Settlement Class Members will release Mohawk from all pending claims, and in exchange Mohawk has agreed to: (i) pay $98,000,000 to a fund to compensate Mohawk Settlement Class Members; (ii) provide limited cooperation at or before trial; and (iii) withdraw its arbitration demand. At Mohawk’s request, the Court previously stayed in favor of arbitration all claims against Mohawk from customers that directly purchased Flexible Polyurethane Foam (including carpet cushion or carpet underlay) from Mohawk during the Class Period and had an arbitration agreement with Mohawk for those purchases. (See Court Order dated August 12, 2014, Docket No. 1311). Mohawk has agreed to withdraw its arbitration demand and the Mohawk Settlement therefore covers and resolves arbitrable claims in addition to the non-arbitrable claims.

Settlement 6: Woodbridge – The “Woodbridge Settlement” is among Plaintiffs, the Certification Class, the Woodbridge Settlement Class, and Woodbridge only. Plaintiffs, Certification Class members, and Woodbridge Settlement Class Members will release Woodbridge from all pending claims, and in exchange Woodbridge has agreed to: (i) pay $50,000,000 to a fund to compensate Woodbridge Settlement Class Members; and (ii) provide limited cooperation at or before trial.

Note that Settlement funds may be reduced by attorneys’ fees and reimbursement of litigation expenses, as approved by the Court. This may include administration of the Settlements. These Settlement Classes and the Certification Class are represented by William A. Isaacson of BOIES, SCHILLER & FLEXNER LLP and Stephen R. Neuwirth of QUINN EMANUEL URQUHART & SULLIVAN, LLP. The motion by Class Counsel for attorneys’ fees and costs and an incentive award for the Representative Plaintiffs will be available for viewing on the Settlement Website after it is filed. After that time, if you wish to review the motion or additional details on how funds will be allocated, you may do so by visiting www.flexiblepolyurethanefoamsettlement.com.

What is this lawsuit about?

The lawsuit is known as In re Polyurethane Foam Antitrust Litigation, Case No. 10-md-2196, and is pending in the United States District Court for the Northern District of Ohio, in Toledo. Direct purchasers of Flexible Polyurethane Foam allege that Defendants conspired to fix, raise, stabilize, or maintain the prices and allocate territories or customers of Flexible Polyurethane Foam, in violation of antitrust laws. As used herein, Flexible Polyurethane Foam includes both “slabstock” flexible polyurethane foam (also known as “block” foam), fabricated or converted foam products made from “slabstock” flexible polyurethane foam, and carpet underlay (also known as “carpet cushion,” “carpet pad” or “carpet padding”) manufactured from polyurethane foam. The term Flexible Polyurethane Foam does not include “molded” foam (also known as “engineered” foam) or “rigid” foam (also known as “technical” foam). Important Court Documents containing more detailed allegations and additional descriptions of the uses and applications of Flexible Polyurethane Foam can be found at the Settlement Website: www.flexiblepolyurethanefoamsettlement.com.

Who is a Class Member?

You are a member of all six Settlement Classes, as well as the Certification Class, if you are among: All persons or entities that purchased Flexible Polyurethane Foam (but excluding molded foam) directly from Defendants and/or their co-conspirators from January 1, 1999 to July 31, 2010 for purchase from or delivery into the United States. Excluded from all six Settlement Classes and the Certification Class are governmental entities, Defendants, their alleged co-conspirators, and their officers, employees, agents, representatives, parents, subsidiaries and affiliates. Also excluded from all six Settlement Classes and the Certification Class are those who timely and validly opted out of the Certification Class on or before January 26, 2015 and/or who were deemed by the Court to have validly opted out of the Certification Class despite an untimely exclusion request (Dkt. 1540). In addition, excluded from the six Settlement Classes and the Certification Class are those who validly and timely elect to exclude themselves from those Classes by September 15, 2015.

Who are the Defendants?

The companies Plaintiffs sued are called Defendants. The following Defendants previously entered into settlements with Plaintiffs: Leggett & Platt, Incorporated (“Leggett & Platt”), Carpenter Co., E. R. Carpenter, L.P., and Carpenter Holdings, Inc. (collectively “Carpenter”); Vitafoam, Inc. and Vitafoam Products Canada Limited (collectively “Vitafoam”); Domfoam International Inc. and Valle Foam Industries (1995) Inc. (collectively Domfoam/Valle Foam). FFP, FXI, Future Foam, Hickory Springs, Mohawk, and Woodbridge—the six settling Defendants—are all of the remaining Defendants in this case.

How do I receive a payment?

To receive a payment from any of the Settlements, you must submit a Claim Form. To request a Claim Form, you may visit www.flexiblepolyurethanefoamsettlement.com or contact the Notice Administrator at 1-888-331-9196. If you previously submitted a Claim Form in connection with the Vitafoam, Leggett & Platt, or Carpenter Settlements, you do not need to submit another Claim Form.

What are my rights and options?

  • Take no action: You will receive the non-monetary benefits of the Settlements. You will give up the right to sue FFP, FXI, Future Foam, Hickory Springs, Mohawk, and Woodbridge with respect to the claims asserted in this case. You may be eligible to receive a payment from the Settlements if you submit a timely Claim Form by September 15, 2015, or previously submitted a Claim Form in connection with the previous settlements.
  • Exclude yourself from any of the Settlement Classes and the Certification Class: This is the only option that allows you to ever be a part of any other lawsuit against FFP, FXI, Future Foam, Hickory Springs, Mohawk, or Woodbridge with respect to the claims asserted in this case. You can choose to exclude yourself from all or some of the Settlements. However, you can be part of a lawsuit against one or more of these settling Defendants only if you exclude yourself both from the applicable Settlement Class and the Certification Class. The Settlements resolve the claims of all of the Settlement Classes and the Certification Class. Accordingly, if you opt out only from the Settlement Class(es), you will still be bound by the Certification Class’s Settlement with the applicable Defendant(s), unless you also opt out of the Certification Class. The deadline to exclude yourself from any of the six Settlement Classes and the Certification Class is September 15, 2015. If you already elected to exclude yourself from the Certification Class by the previously-established January 26, 2015 deadline, and/or you were deemed by the Court to have validly opted out of the Certification Class despite an untimely exclusion request (Dkt. 1540), you are considered excluded from all six Settlement Classes and the Certification Class, and do not need to resubmit any exclusion request.
  • Exclude yourself from any of the Settlement Classes and not the Certification Class: If you elect to exclude yourself from any of the Settlement Classes, but do not also elect to exclude yourself from the Certification Class, you will give up the right to all non-monetary and monetary benefits of the Settlement(s) from which you have excluded yourself. You will still be considered part of the Certification Class. The Settlements release the claims of the Certification Class, and, if the Settlements are approved by the Court, the claims of the Certification Class will be dismissed. As a result, if you elect to remain a member of the Certification Class, you will not be able to be a part of any other lawsuit against any of the settling Defendants with respect to the claims asserted in this case.
  • Object to one or more of the six Settlements: You can remain in the Settlement Classes and object to or comment on any term of the Settlements. You may explain to the Court in writing why you do not like one or more of the Settlements. Even if you object to a Settlement or proposed Settlement Class, you will remain a member of that proposed Settlement Class. You can exclude yourself from some of the Settlements, but still object to the other Settlements from which you do not exclude yourself. The deadline to object is September 15, 2015.

When is the Fairness Hearing?

The Court has scheduled a “Fairness Hearing” on October 9, 2015 at 10:00 a.m., at the following address:

United States District Court
James M. Ashley and Thomas W. L. Ashley U.S. Courthouse
1716 Spielbusch Avenue
Toledo, OH 43604

The purpose of the Fairness Hearing is to determine whether the Settlements are fair, reasonable, and adequate, whether the Court should grant final approval of the Settlements, and whether the Court should enter a final Judgment of dismissal of the lawsuit as to FFP, FXI, Future Foam, Hickory Springs, Mohawk, and Woodbridge with prejudice. The Court will also consider the motion for attorneys’ fees. You do not need to attend this hearing. You or your own lawyer may attend the hearing if you wish, at your own expense. Members of the Settlement Classes are advised to check the Settlement Website for any updates.

Where do I get additional information?

This Notice is only a summary. For more detailed information about the Settlements, you may review documents available at www.flexiblepolyurethanefoamsettlement.com. You may also obtain more information by contacting the Notice Administrator at 1-888-331-9196 or send your questions to In re Polyurethane Foam Antitrust Litigation, c/o GCG, P.O. Box 9907, Dublin, OH 43017-5807.

PLEASE DO NOT CONTACT DEFENDANTS OR THE COURT FOR INFORMATION REGARDING THIS LAWSUIT.

1 As used in this Notice, “Certification Class” refers to the Direct Purchaser Class, as that class was certified and defined in the Court’s April 16, 2014 Order (Dkt. 1115). “[Defendant] Settlement Class” refers to the respective Settlement Classes defined in each Settlement. Those Settlements and the full language of the applicable releases are available at www.flexiblepolyurethanefoamsettlement.com.


50 Years of Diabetes Research and Treatment

0





50 Years of Diabetes Research and Treatment

Perspectives from Physicians, Researchers and Patients on How the Past Five Decades Have Changed What We Know About and How People Live with Diabetes


BOSTON, June 6, 2015 /PRNewswire-HISPANIC PR WIRE/ — From how people test their glucose levels to how long they can expect to live, almost everything has changed over the past 50 years for Americans with diabetes. A special symposium held at the American Diabetes Association’s 75th Scientific Sessions features a look back at what physicians and researchers have learned and how the lives of patients have changed during the past five decades.

Logo – http://photos.prnewswire.com/prnh/20141105/156803LOGO

“There are things that have happened over the past 50 years that clearly make life a lot better for people,” said Fred Whitehouse, MD, Division Head Emeritus at the Henry Ford Health System in Detroit, who has been treating people with diabetes for just as long.

For example, when Whitehouse first started seeing patients the only option for the treatment of type 1 diabetes was to inject animal insulin, which came from cows or pigs and sometimes caused adverse reactions in people. Today, human insulin produced by microorganisms is used, an important difference because not only are there fewer adverse reactions, there’s no fear of running out of it, he said. What’s more, there are now long- and rapid-acting insulins and a variety of delivery systems, including insulin pumps, which improve accuracy and comfort while tightening blood glucose control and reducing hypoglycemia.

The way glucose levels are tested has also changed dramatically, said Whitehouse. Whereas once the only way to assess diabetes control was by testing for the presence of sugar in a person’s urine, today there are numerous, far more accurate ways to test blood glucose levels, including the non-invasive A1C, which measures average blood glucose levels over a three-month period. “This gives us a nice marker for showing whether a person is on the right road or not,” Whitehouse said.  

Yet there is still a long way to go, he noted. “There’s been a lot of change, most of it for the better, but what people want is a cure and we don’t have that yet.”

Daniel Porte, Jr., MD, has been conducting diabetes research for more than 50 years and has witnessed a sea of change in how much is known about the mechanisms involved in diabetes. He remembers when the endocrine and nervous systems were considered completely unrelated, when glucose was considered the only regulator of insulin and when there was only one method for administering insulin. While researchers have learned much about diabetes over the past 50 years – including how it develops, how to prevent or delay it and how it affects the rest of the body, all of which were virtually unknown in the 1960s – perhaps the most important lesson, he said, is that the fruits of investigation don’t ripen overnight.

“In order to understand disease, you have to do basic research,” said Porte, a professor at the University of California, San Diego and professor emeritus at the University of Washington. “But you’ve got to be patient, because it takes a long time to go from basic research to clinical impact.”

“For example,” he said, “the drugs we use now to treat diabetes were first studied 30 to 40 years ago. And there are many more than the one or two that were being used back in the 1970s.”

During the time Porte has been involved in diabetes research, the field has grown from taking simple measurements of hormones to increasingly complex investigations that look at the inter-relationship between hormones and the nervous system, an area still being plumbed for new discoveries. “This year, amazingly enough to me,” he said, “it was discovered that insulin sent to the central nervous system not only feeds back to the brain, it also affects glucose production. It regulates the islet cells, so there is a complete integration of the endocrine system and the nervous system. It took 40 years to discover this.”

Not only do these discoveries help us develop better treatments for diabetes, said Porte, they can also help in the treatment of other diseases, such as Alzheimer’s. “We now believe that perhaps impaired insulin action in the central nervous system leads to the behavioral changes we see in Alzheimer’s patients,” he said.

Michael Brownlee, who has experienced life as a person with diabetes, physician and researcher, said the one thread that ties all three roles together is the issue of diabetes-related complications.

“The reason diabetes is a serious health problem is because of the complications,” said Brownlee, Anita and Jack Saltz Chair in Diabetes Research and Associate Director for Biomedical Sciences at the Albert Einstein College of Medicine’s Diabetes Research Center. “If there were no complications, diabetes would be like hypothyroidism and other easily managed diseases. You’d take a tablet to replace the hormone and everything would be fine. It wouldn’t be a public health problem costing billions of dollars in care each year and requiring billions of dollars of research.”

Brownlee, diagnosed with type 1 diabetes at age 8, has suffered from the two potentially fatal acute complications of this disease – ketoacidosis and severe hypoglycemia – but not from any of the chronic complications that cause blindness, kidney failure, and heart attacks.  He remembers applying to medical school at a time when only half of people with type 1 diabetes were expected to live into their 40’s or early 50’s. Some schools were reluctant to admit him because he “wouldn’t be able to practice medicine for a full lifetime,” he said. “They said they’d rather give the spot to someone with a normal lifespan. Fortunately, advances in diabetes research and treatment have made those old statistics obsolete.”  

Brownlee’s research on the mechanisms that cause diabetic complications has created a paradigm shift in the field. He noted that until 1993, diabetes complications – such as eye and kidney disease – were considered  consequences of diabetes, rather than of high blood glucose levels. “Prior to the Diabetes Control and Complications Trial (DCCT) study that was published that year, the general dogma was that diabetes caused both metabolic changes and complications, which had nothing to do with each other. They were just two parallel manifestations of the disease,” he said.

“Now it’s known that prolonged high glucose levels increase the risk for eye and kidney complications associated with diabetes, and maintaining tighter control of blood glucose levels reduces that risk,” he said.  “We also learned from EDIC, the follow-up study to the DCCT,  that the adverse effects of early high blood glucose levels persist for many years after A1Cs are improved, a phenomenon called ‘metabolic memory’.” A major focus of his current research is identifying the mechanisms responsible for metabolic memory.

Kathryn Ham, who turns 86 this week, has seen tremendous changes in the treatment of diabetes over the 78 years she has been living with type 1 diabetes. But she also believes firmly in the importance of keeping some things the same – such as when she gives herself insulin each day and when she tests her blood glucose levels. That kind of discipline, she said, prevents her from making mistakes or forgetting to take her insulin.

“Every person with diabetes needs to create a system for remembering and/or dealing with his or her own treatment,” she said. “My system, though antiquated, works for me. I still inject insulin four times per day.  I have a cup into which I put the used testing needle and used insulin needle.  If I am interrupted, for example by a telephone call, while administering treatment, I can look in the cup to see if I have already taken my insulin, because I am forgetful.  Of course nowadays, use of an insulin pump renders this unnecessary for many people, but there are always things you need to remember so dream up your own system.”

Over the years, Ham said, she has seen the needles grow smaller, and the addition of the A1C blood glucose test, new forms of insulin, new treatments for diabetes-related eye disease and the introduction of digital blood glucose meters, “which have all made a tremendous difference in diabetes care.”

“Despite the enormous growth in our understanding of diabetes and its complications, we are still only able to manage the disease,” said Robert Ratner, Chief Scientific and Medical Officer for the American Diabetes Association.  “The next 50 years must elucidate the mechanisms by which both type 1 and type 2 diabetes occur, along with those critical steps at which we might intervene to prevent disease.  Treatments must provide optimal glucose and metabolic control, without the risk of hypoglycemia, and complications of diabetes should become historical memories.”

The American Diabetes Association is leading the fight to Stop Diabetes®  and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. For the past 75 years, our mission has been to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (800-342-2383) or visit diabetes.org. Information from both these sources is available in English and Spanish.

 


Dr. Russell Moore to Join NHCLC Board to Help Ignite New Generation of Hispanic Leaders

0





Dr. Russell Moore to Join NHCLC Board to Help Ignite New Generation of Hispanic Leaders

Appointment emphasizes commitment to religious freedom, justice


SACRAMENTO, Calif., June 5, 2015 /PRNewswire-HISPANIC PR WIRE/ — Reverend Samuel Rodriguez and the National Hispanic Christian Leadership Conference (NHCLC) announces evangelical theologian, ethicist and minister Dr. Russell Moore to its organizational board.

“I am happy to join my friends at the National Hispanic Christian Leadership Conference,” Moore said. “I pray that God would enable us, together, to raise up a new generation of gospel-centered Hispanic leaders to evangelize the Americas and the rest of the world for the glory of Jesus Christ.”

Moore serves as president of the Southern Baptist Ethics and Religious Liberty Commission, which is the nation’s largest Protestant denomination moral and public policy agency.

Moore has partnered with Rodriguez and NHCLC on a number of initiatives in the past including the 21 Martyrs Campaign. Moore was also a keynote speaker at the 2015 NHCLC National Convention along with presidential candidate Gov. Mike Huckabee, presumed candidate Gov. Jeb Bush and U.S. Congressman Luis Gutierrez (D-Ill.)

“The nomination of Dr. Moore to the board emphasizes one of our most important directives and goals of the immediate future—the cause of religious liberty and freedom here in the United States and around the world,” said Dr. Samuel Rodriguez, president of NHCLC. “We look forward to having him join our efforts to spread to fight for justice during this critical time.”

NHCLC/CONEL is the world’s largest Hispanic Christian organization. It serves as a representative voice for the more than 100 million Hispanic Evangelicals assembled in over 40,000 U.S. churches and another 500,000 congregations spread throughout the Spanish-speaking diaspora. The organization seeks to reconcile Evangelist Billy Graham’s message of salvation through Christ with Dr. Martin Luther King, Jr.’s march of prophetic activism. A bipartisan organization, NHCLC/CONEL follows the agenda of the Lamb, not the donkey or the elephant, and emphasizes “7 Directives” of Life, Family, Compassionate Evangelism, Stewardship, Justice, Education and Youth. For additional information, visit http://www.nhclc.org.